Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Marc CarrierKarim Abou-NassarRanjeeta MallickVicky TagalakisSudeep ShivakumarAriah SchattnerPhilip KuruvillaDanny HillSilvana SpadaforaKaterine MarquisMateya TrinkausAnna TomiakAgnes Y Y LeePeter L GrossAlejandro Lazo-LangnerRobert El-MaraghiGlenwood GossGregoire Le GalDavid StewartTimothy RamsayMarc RodgerDebra WithamPhilip S Wellsnull nullPublished in: The New England journal of medicine (2018)
Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy. The rate of major bleeding episodes was higher with apixaban than with placebo. (Funded by the Canadian Institutes of Health Research and Bristol-Myers Squibb-Pfizer Alliance; AVERT ClinicalTrials.gov number, NCT02048865.).